| Literature DB >> 31014509 |
Júlia Coelho França Quintanilha1, Kathleen Francinette Saavedra2, Marília Berlofa Visacri3, Patricia Moriel4, Luis A Salazar5.
Abstract
Cisplatin (CDDP) is a highly effective antineoplastic agent, widely used in the treatment of various malignant tumors. However, its major problems are side effects associated to toxicity. Considerable inter-individual differences have been reported for CDDP-induced toxicity due to genetic and epigenetic factors. Genetic causes are well described; however, epigenetic modifications are not fully addressed. In the last few years, many evidences were found linking microRNA to the development of CDDP-mediated toxicity, particularly nephrotoxicity. In this review, we described how genetic and epigenetic modifications can be important determinants for the development of toxicity in patients treated with CDDP, and how these alterations may be interesting biomarkers for monitoring toxicity induced by CDDP. Considering the validation in different studies, we suggest that miR-34a, -146b, -378a, -192, and -193 represent an attractive study group to evaluate potential biomarkers to detect CDDP-related nephrotoxicity.Entities:
Keywords: Cisplatin; Drug-induced toxicity; Epigenetics; Methylation; microRNA
Mesh：
Substances：
Year: 2019 PMID： 31014509 DOI： 10.1016/j.critrevonc.2019.03.004
Source DB: PubMed Journal: Crit Rev Oncol Hematol ISSN： 1040-8428 Impact factor: 6.312